Global Opioid Withdrawal Syndrome Market
Global Opioid Withdrawal Syndrome market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.
Opioids are a class of drugs that are used to manage pain including morphine, heroin, codeine, oxycontin, hydromorphone, and methadone. Opioid withdrawal syndrome is a condition that results from over-dependence on opioids. These are the most common forms of drugs that are misused in the US, Europe, and Asia leading to premature mortality in these regions.
Opioid dependence cannot be known with diagnostic tests except urine toxicology which gives the measure of opioid intake. Usually, COWS (Clinical Opioid Withdrawal Scale) is the direct measure that is used to know the severity of opioid withdrawal.
Market Dynamics: Drivers & Restraints
Increasing Awareness campaigns about opioid usage
Opioid dependence has increased among people in Western countries due to drug abuse and the availability of OTC drugs. Opioid withdrawal syndrome is sometimes lethal to the patient's body. High-income and middle-income countries are taking many initiatives to stop drug abuse and illegal use of drugs which lowers the opioid dependency among young individuals. Increasing awareness programs and initiatives are the driving forces for reducing the incidence of opioid withdrawal syndrome.
For instance, according to December 2022, the MAT Act has eliminated the DATA-Waiver (X-Waiver) program. All DEA-registered practitioners with schedule III authority prescribe buprenorphine for opioid use disorder (OUD) in their practice if permitted by applicable state law. Furthermore, according to the California Department of Public Health, 2023, launched its first phase of opioid and Fentanyl overdose prevention and education campaign. This is anticipated to continue till 2025.
Side effects of opioid withdrawal drugs
Side effects of opioids include nausea, respiratory depression, vomiting, etc. These side effects arise due to the addiction to opioids even as a treatment. Physical dependance is one of the main clinical concerns caused due to treatment addiction. Drugs like buprenorphine should be given with caution to the patient having a health history of diabetes, respiratory deficiency, and urethral obstruction. Sometimes drug relapse is very common in patients who completed the withdrawal management treatment.
Segment Analysis
The global opioid withdrawal syndrome market is segmented based on drug type, route of administration, distribution channel and region.
Buprenorphine Drug Class is Expected to Dominate Market
Buprenorphine is expected to hold the largest share of the market owing to the launches in the market. These are launched in combination with other drugs for better efficiency in treating opioid withdrawal syndrome in patients who are highly dependent on opioids for survival. The market is expected to be driven by the launch of these drugs.
For instance, in September 2023, Braeburn launched BRIXADI (buprenorphine) extended released injection in the US for subcutaneous use, which is used for the treatment of moderate to severe opioid use disorder (OUD). Also, in May 2023, Accord Healthcare launched Zubsolv Buprenorphine and Naloxone sublingual tablets which are used to treat dependence on opioid drugs in adolescents and adults over 15 years of age.
Geographical Analysis
North America is Expected to Dominate the Global Market
North America is expected to hold the largest market share owing to the incidences of drug abuse among young individuals. For instance, according to the National Center for Drug Abuse Statistics, 2023, approximately 67.8% of deaths due to drugs are caused by opioids followed by other psychostimulants like cocaine, methadone, etc.
Furthermore, according to the New England Journal of Medicine, there is an alarming trend in the United States of increased availability, higher purity, and lower prices of illegal drugs, particularly heroin and cocaine. Dealers are adulterating these drugs with fentanyl, a highly potent drug that is 30 to 50 times more powerful than heroin, and manufacturing counterfeit prescription drugs that are made with fentanyl. As a result, the drugs being sold on the streets are more powerful, more addictive, and more dangerous than ever before.
Market Segmentation
By Drug Type
• Lucemyra
• Methadone
• Buprenorphine
• Naltrexone
• Others
By Route of Administration
• Oral
• Intravenous
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In May 2023, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD).
• In September 2023, Camurus launched Brixadi in the US for the treatment of moderate to severe opioid use disorder by Braeburn.
Competitive Landscape
The major global players in the opioid withdrawal syndrome market include USWM, LLC, Teva Pharmaceuticals USA, Inc., Braeburn Inc, Rosemont Pharmaceuticals Ltd, Mallinckrodt, Pfizer Inc, Alkermes, Inc, Vista Pharm LLC, Steris Healthcare Pvt Ltd, Accord Healthcare Inc among others.
Why Purchase the Report?
• To visualize the global opioid withdrawal syndrome market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of opioid withdrawal syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global opioid withdrawal syndrome market report would provide approximately 58 tables, 58 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Drug Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Distribution Channel
- 3.4. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Awareness campaigns about opioid usage
- 4.1.1.2. YY
- 4.1.2. Restraints
- 4.1.2.1. Side effects of opioid withdrawal drugs
- 4.1.2.2. YY
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. Pipeline Analysis
- 5.7. Epidemiology
- 5.8. SWOT Analysis
- 5.9. DMI Opinion
- 6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
- 7. By Drug Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Lucemyra*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Methadone
- 7.4. Buprenorphine
- 7.5. Naltrexone
- 7.6. Others
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Intravenous
- 9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
- 10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. UK
- 10.3.6.3. France
- 10.3.6.4. Italy
- 10.3.6.5. Spain
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
- 10.5.6.4. Australia
- 10.5.6.5. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
- 12. Company Profiles
- 12.1. USWM, LLC*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Teva Pharmaceuticals USA, Inc.
- 12.3. Braeburn Inc
- 12.4. Rosemont Pharmaceuticals Ltd
- 12.5. Mallinckrodt
- 12.6. Pfizer Inc
- 12.7. Alkermes, Inc
- 12.8. Vista Pharm LLC
- 12.9. Steris Healthcare Pvt Ltd
- 12.10. Accord Healthcare Inc
- LIST NOT EXHAUSTIVE
- 13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook